Company: ENTXW
Filing Date: 2025-05-30
Form Type: S-3
Source: 0001178913-25-002025
Chunk: 36

Company: Entera Bio Ltd.
Filing Date: 2025-05-30
Form: S-3
Chunk 36
---
 additional funding; |

| • | announcements of research activities, business developments, technological innovations or new products, or acquisitions or expansion plans by us or our competitors; |

| • | success or failure of our research and development projects or those of our competitors; |

| • | our entering into or terminating strategic relationships; |

| • | changes in laws or government regulation; |

| • | actual or anticipated fluctuations in our and our competitors’ results of operations and financial condition; |

| • | regulatory developments and the decisions of regulatory authorities as to the approval or rejection of new or modified products; |

| • | departure of our key personnel; |

| • | disputes related to proprietary rights, including patents, litigation matters and our ability to obtain intellectual property protection for our technologies; |

| • | our sale, or the sale by our significant shareholders, of ordinary shares or other securities in the future; |

| • | public concern regarding the safety, efficacy or other aspects of the products or methodologies we are developing; |

| • | market conditions in our industry and changes in estimates of the future size and growth rate of our markets; |

| • | market acceptance of our products; |

| • | the mix of products that we sell and related services that we provide; |

| • | the success or failure of our licensees to develop, obtain approval for and commercialize our licensed products, for which we are entitled to contingent payments and royalties; |

| • | publication of the results of preclinical or clinical trials for EB613, EB612 or any other product candidates we may develop; including the oral GLP-2 and OXM programs we are developing with OPKO Health, Inc.; |

| • | failure by us to achieve a publicly announced milestone; |

| • | delays between our expenditures to develop and market new or enhanced products and the generation of sales from those products; |

S-4

| • | changes in the amounts that we spend to develop, acquire or license new products, technologies or businesses; |

| • | changes in our expenditures to promote our products; |

| • | variance in our financial performance from the expectations of market analysts; |

| • | the limited trading volume of our ordinary shares; and |

| • | general economic and market conditions, including factors unrelated to our industry or operating performance. |

In addition, the stock market in general has recently experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of individual companies. Broad market and industry factors may materially affect